This is the first of a series looking at the burgeoning Medicinal Psychedelics industry, of which MindBio Therapeutics is a leading player. Justin Hanka, co-founder and director of MindBio Therapeutics, talks about why, as an investment banker he got involved in medicinal psychedelics, and what excites him about the research.
Medicinal Psychedelics are making quite a noise on the global investment markets, MindBio Therapeutics is one business in this space. In this video, Justin Hanka explains a little about why he got involved in MindBio and why there is an investment buzz around the industry. MindBio Therapeutics is a clinical-stage drug development company that is pioneering psychedelic microdosing. With its first candidate drug LSD currently in Phase 1 clinical trials microdosing LSD in 80 healthy participants. In a world-first clinical trial of its kind, participants are prescribed the microdoses to take home with them after receiving a battery of psychological and biometric baseline tests in the laboratory. Phase 2 clinical trials microdosing LSD have just been approved in late-stage cancer patients experiencing existential distress, anxiety and depression. MindBio Therapeutics has a unique drug formulation strategy that will integrate with artificial intelligence and technology development for the enhanced safety, optimal dosing and monitoring of patients. #mentalhealth #microdosing #mindbio #AlbertHofmann #LSD
In this episode we have a chat with Justin Hanka from MindBio Therapeutics on the research they are undertaking, and why he got involved.
© 2020-2025 Ivy Podcast Discovery LLC
